CVS Health Corp (NYSE:CVS) is posting a narrower earnings target for full-year 2014. It also reported stronger-than-expected results for Q3 ended September 30. The pharmacy benefit management company said adjusted EPS rose 9% from last year to $1.15, benefiting from a 9.7% year-over-year climb in net revenues to $35 billion. The mean estimate was for adjusted EPS of $1.13 and net revenues of $34.7 billion.President and CEO Larry Merlo said the results in the quarter reflect revenue growth across the enterprise, with the pharmacy services and retail pharmacy segments increasing revenues by 15.7% and 3.1%, respectively. For full-year 2014, however, the company narrowed its adjusted EPS forecast to a new range of $4.47 to $4.50 from the previous range of $4.43 to $4.51. For Q4, adjusted EPS is expected to be $1.18 to $1.21. The Street is at $4.49 per share for the year and $1.21 per share for Q4. CVS Health Corp (NYSE:CVS) closed up to $86.12 on Monday, within a 52-week range of $61.92 - $87.16.Sagent Pharmaceuticals Inc (NASDAQ:SGNT) reported Q3 earnings and sales that were ahead of analysts' estimates. The injectable pharmaceutical company said net income fell to $1.93 million or $0.06 per share from $2.83 million or $0.10 the yea earlier. The income included $0.9 million in acquisition related costs, or costs of $0.02 per-share after tax. Analysts polled by Capital IQ had expected EPS of $0.01. Revenue rose 7% to $65.4 million, also coming in ahead of the $64.01 million consensus. For 2014, Sagent Pharmaceuticals Inc (NASDAQ:SGNT) said it expects revenue between $275 million to $285 million, exceeding the $274 million consensus estimate. Net income is expected to be between $5 million and $10 million. SGNT is trading in the upper half of the 52-week range between $17.49 and $33.60.Allot Communications Ltd (NASDAQ:ALLT), a supplier of service optimization and revenue generation solutions for broadband and cloud providers, announced Q3 results that beat the Street view on both EPS and total revenues as the company names a new Chief Financial Officer. The company reported Q3 EPS of $0.09, up from $0.03 in Q3 2013 and beating analyst estimates of $0.08 for the quarter. Total revenues of $30.10 million were up from $23.94 million in Q3 2013 and topped analyst projections of $29.27 million.Allot Communications Ltd (NASDAQ:ALLT) also announced the appointment of Shmuel Arvatz as CFO. Arvatz will replace Nachum Falek, who is leaving to become the CFO of a privately-held company. Prior to joining Allot, Arvatz served as the CFO of ClickSoftware, a provider of automated mobile workforce management solutions. Shares of ALLT are trading within a 52-week range of $9.41 - $18.09.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
